

RESEARCH

Open Access

Sudden unexpected fatal encephalopathy in adults with *OTC* gene mutations-Clues for early diagnosis and timely treatment

Catia Cavicchi¹, Maria Alice Donati², Rossella Parini³, Miriam Rigoldi³, Mauro Bernardi⁴, Francesca Orfei⁵, Nicolò Gentiloni Silveri⁶, Aniello Colasante⁷, Silvia Funghini⁸, Serena Catarzi¹, Elisabetta Pasquini², Giancarlo la Marca^{8,9}, Sean David Mooney¹⁰, Renzo Guerrini^{9,11} and Amelia Morrone^{1,9*}

Abstract

Background: X-linked Ornithine Transcarbamylase deficiency (OTCD) is often unrecognized in adults, as clinical manifestations are non-specific, often episodic and unmasked by precipitants, and laboratory findings can be normal outside the acute phase. It may thus be associated with significant mortality if not promptly recognized and treated. The aim of this study was to provide clues for recognition of OTCD in adults and analyze the environmental factors that, interacting with *OTC* gene mutations, might have triggered acute clinical manifestations.

Methods: We carried out a clinical, biochemical and molecular study on five unrelated adult patients (one female and four males) with late onset OTCD, who presented to the Emergency Department (ED) with initial fatal encephalopathy. The molecular study consisted of *OTC* gene sequencing in the probands and family members and *in silico* characterization of the newly detected mutations.

Results: We identified two new, c.119G>T (p.Arg40Leu) and c.314G>A (p.Gly105Glu), and three known *OTC* mutations. Both new mutations were predicted to cause a structural destabilization, correlating with late onset OTCD. We also identified, among the family members, 8 heterozygous females and 2 hemizygous asymptomatic males. Patients' histories revealed potential environmental triggering factors, including steroid treatment, chemotherapy, diet changes and hormone therapy for in vitro fertilization.

Conclusions: This report raises awareness of the ED medical staff in considering OTCD in the differential diagnosis of sudden neurological and behavioural disorders associated with hyperammonemia at any age and in both genders. It also widens the knowledge about combined effect of genetic and environmental factors in determining the phenotypic expression of OTCD.

Keywords: Urea Cycle Disorders (UCD), Ornithine transcarbamylase deficiency (OTCD), Late onset OTCD, *OTC* gene mutations, Hyperammonemic encephalopathy, Environmental triggering factors for hyperammonemia

* Correspondence: amelia.morrone@unifi.it

¹Molecular and Cell Biology Laboratory, Pediatric Neurology Unit and Laboratories, Neuroscience Department, A. Meyer Children's Hospital, Viale Pieraccini 24, 50139 Florence, Italy

⁹Department of Neurosciences, Psychology, Pharmacology and Child Health, University of Florence, Florence, Italy

Full list of author information is available at the end of the article

Background

Ornithine transcarbamylase deficiency (OTCD; OMIM 311250), the most common urea cycle disorder (UCD), is caused by a defect of the mitochondrial ornithine transcarbamylase (OTC, EC 2.1.3.3). The mature OTC enzyme, a trimer, catalyses the synthesis of citrulline from carbamyl phosphate (CP) and ornithine (ORN) in the liver and small intestine [1].

OTCD is an X-linked disorder due to deleterious mutations in the *OTC* gene in Xp21.1 and is characterized by high molecular heterogeneity with about 435 mutations having been described (HGMD: <http://www.biobase-international.com/product/hgmd>). Severe *OTC* gene mutations with no residual enzyme activity in hemizygous males lead to hyperammonemic coma in the neonatal period or in early infancy, which is often fatal. Some affected males may, however, exhibit a delayed onset of the disease, the so called "late onset OTCD" (LO-OTCD) [2]. The number of reported LO-OTCD patients is increasing [3], but only a few had remained essentially asymptomatic until acute onset in adulthood. In hemizygous male patients the phenotype is determined by several conditions, including the type of mutation but also other yet unknown factors such as environment and/or other genes. In heterozygous females phenotypic severity is also influenced by the X-inactivation pattern [1].

Without early diagnosis and intervention, the prognosis of OTCD with acute hyperammonemia is poor. The emergency management of hyperammonemia is based on: a) reversal of the catabolic state through glucose supplementation and halted protein intake, b) pharmacological removal of ammonia by sodium benzoate, sodium phenylacetate or sodium phenylbutyrate administration and c) extracorporeal detoxification of ammonia by dialysis [4,5]. L-arginine and/or L-citrulline supplementation promote ammonia excretion through the urea cycle [4]. Hypothermia may be a neuroprotective measure, but its efficacy has not yet been proven in randomized controlled trials [6]. Guidelines for the diagnosis and management of UCD have been recently drawn up in order to provide a general consensus to guide practitioners and set standards of care [4].

We report a clinical, biochemical and molecular study of five adults with OTCD who developed *de novo* fatal hyperammonemic encephalopathy. We also present the *in silico* characterization of the newly detected *OTC* gene mutations and discuss the environmental events that, interacting with *OTC* mutations, might have triggered acute clinical manifestations.

Methods

Patients

Patients were adults referred to our diagnostic laboratory because of clinical suspicion of a UCD, and their relatives. Informed consent to the investigation, according to the

Declaration of Helsinki and approved by the Human Research Ethics Committee of the Meyer's University Hospital, was obtained from all subjects.

Biochemical assays

Plasma amino acid analysis was performed by ion-exchange chromatography on a Biochrom 30 amino acid analyzer (Cambridge, UK) using the manufacturer's standard protocol.

Quantification of orotic acid in urine was performed by LC-MS/MS (Toronto, Canada) as previously described [7].

Detection of *OTC* gene mutations

Genomic DNA was isolated from peripheral blood using a QIA Symphony instrument as recommended by the manufacturer (Qiagen, Hilden, Germany). The entire coding region and intron-exon boundaries of the *OTC* gene were amplified by PCR as previously reported [8]. PCR fragments were separated on a 2% agarose gel, visualized with a UV transilluminator and then purified using Exo-SAP-IT (USB Corporation, Cleveland, OH, U.S.A.).

Mutation analysis was performed by direct sequencing of the double-stranded purified products using the BigDye Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, U.S.A.). Sequencing reactions were purified using Sephadex G-50 Fine (GE Healthcare, Little Chalfont, UK) and capillary electrophoresis was performed on ABI PRISM 3130 Genetic Analyser (Applied Biosystems) as recommended by the manufacturer.

All mutations are described according to guidelines of the Human Genomic Variation Society (HGVS) (<http://www.hgvs.org/mutnomen/>) and using the NM_000531.3 and NP_000522.3 reference sequences (<http://www.ncbi.nlm.nih.gov/gene/>).

Screening of new *OTC* mutations

The Human Gene Mutation Database (HGMD) (<http://www.biobase-international.com/product/hgmd>) was analyzed for investigating the novelty of mutations identified. The two new point mutations were subsequently examined in the 1000 Genomes project database (<http://browser.1000genomes.org/index.html>). In addition, we screened by sequencing analysis the *OTC* gene of 100 DNA samples from healthy males to estimate the frequency of new mutations in the Italian population.

Bioinformatic analyses of new *OTC* mutations

We downloaded the crystal structure for human OTC protein [PDB: 1OTH] for structural analysis of the mutant OTC enzyme. The 2D structure boundaries and solvent accessibility were calculated with the Stride program [9].

Stability changes in OTC protein introduced by mutations were predicted by IMutant 2.0 [10]. Structure-

based predictions were performed *in silico* at pH 7 and 37°C.

Knowledge about catalytic residues and substrate binding sites was obtained from the literature [11,12]. Effects of mutations on the trimeric protein were predicted based on PDB entry 1FVO. Inter-residue contacts were studied with the CSU program [13].

For conservation analysis, 18 homologous sequences (10 from eukaryotes and 8 from bacteria) were aligned by MAFFT E-INS-I [14]. Conservation scores were obtained from the ConSurf program (Bayesian paradigm) [15].

The pathogenicity and functional effects of the new *OTC* mutations were evaluated by SNAP (<http://roslab.org/services/snap/>), PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>) and MutPred (<http://mutpred.mutdb.org/>). The probability threshold for pathogenicity was set to the default value 0.05 for all tools.

Results

Clinical and biochemical investigation

Four Italian men (Pts 1 to 4) and one woman (Pt 5), aged 21 to 66 years, developed initial and fatal hyperammonemic encephalopathy due to undiagnosed LO-OTCD. Their main clinical and laboratory findings are summarized in Tables 1 and 2. Detailed case reports are available in Additional file 1: Text S1.

At the time of the acute episodes, none of the patients had a family history of metabolic disorders or had previous episodes of altered mental status. Interestingly, three patients reported preferring a low-protein diet with large amounts of vegetables.

The clinical course of acute expression of symptoms was similar in all patients, starting with gastrointestinal symptoms and/or impaired awareness, rapidly evolving into deterioration of the mental status and coma within 5 days from onset. Noticeably, in addition to hyperammonemia, hypertransaminasemia and respiratory alkalosis were observed in all patients.

The suspicion of OTCD was biochemically based on altered amino acid profiles and orotic aciduria, which is crucial for distinguishing OTCD from carbamoyl phosphate synthetase I (CPS1) and N-acetylglutamate synthase (NAGS) deficiencies.

After clinical/biochemical suspicion of UCD was established, emergency management of hyperammonemia was started in 4/5 patients, but although in 3/5 patients ammonia levels returned to normal after UCD therapy, exitus ensued.

Molecular investigation

We confirmed OTCD in all patients by post-mortem *OTC* sequence analysis. We identified two novel mutations, c.119G > T (p.Arg40Leu) and c.314G > A (p.Gly105-Glu), and three previously reported mutations, c.119G > A

(p.Arg40His), c.622G > A (p.Ala208Thr) and c.829C > T (p.Arg277Trp). The results of molecular and computational analysis are summarized in Table 3.

None of the new genetic variants was present in the 1000 Genomes Project database or in the Italian control population, suggesting that they are likely to be disease-causing mutations. Noticeably, all three pathogenicity prediction tools, e.g. SNAP, PolyPhen-2 and MutPred, consistently classified both new variants as pathogenic (see Additional file 2: Table S2).

The novel c.119G > T (p.Arg40Leu) mutation, identified at a hemizygous level in Pt 1, affects a CpG dinucleotide in the exon which is also involved in two other known mutations, the c.118C > T (p.Arg40Cys) [16] and c.119G > A (p.Arg40His) [17]. The Arg 40 is a conserved residue of the polar/CP binding domain (residues 34–168 and 345–354) [11], is not in contact with the active site and its side chain is exposed to the surface (Figure 1A).

The novel c.314G > A (p.Gly105Glu) mutation was identified at the hemizygous level in Pt 3. The same nucleotide is also involved in the c.314G > T (p.Gly105Val) mutation that had previously been identified in a female with OCTD [18]. The Gly 105 is a conserved residue mapping in a turn of polar/CP binding domain of the *OTC* protein [11]. In the trimeric *OTC* enzyme the 105 position is located on the top of trimer interface and the three amino acids would be close to each other in the quaternary structure (Figure 1B).

All the known c.119G > A (p.Arg40His), c.622G > A (p.Ala208Thr) and c.829C > T (p.Arg277Trp) mutations have been previously reported in OTCD patients with residual enzymatic activity [17,19,20].

After the probands' characterization the molecular study of the *OTC* gene was extended to family members and led to identification of 8 heterozygous females and 2 additional hemizygous asymptomatic males (Table 3).

Retrospective analysis for potential environmental triggering factors

The retrospective analysis of the patients' histories revealed a number of precipitating environmental factors, including therapy with steroids (Pt 1), diet changes implying poor feeding after dental surgery (Pt 2) and increased dietary protein intake plus food additives (Pt 3), chemotherapy (Pt 4) and hormone therapy for *in vitro* fertilization (Pt 5).

Discussion

Clinical and biochemical clues

OTCD is traditionally identified in pediatric patients [21], while late-onset presentations may remain latent for many years and often go unrecognized. As a consequence, mortality rates may be high if they are not

Table 1 Clinical findings of adult OTCD patients with fatal encephalopathy

	Pt 1 (M)	Pt 2 (M)	Pt 3 (M)	Pt 4 (M)	Pt 5 (F)
ACUTE EPISODE					
Age at fatal acute episode	45 y	44 y	21 y	66 y	34 y
Duration of fatal episode	9 d	30 d	15 d	5 d	22 d
Duration of coma	7 d	1 d (first coma); 7 d (second coma)	12 d	2 d	20 d
FAMILY HISTORY OF METABOLIC DISORDERS	Negative	Negative	Negative	Negative	Negative
PAST MEDICAL HISTORY	Cholecystectomy; Crohn disease; Carpal tunnel syndrome; Sciatica	Chronic Hepatitis B with fluctuating hypertransaminasemia and prothrombin deficiency	Negative	Hypertension; Colon cancer (colectomy and oxaliplatin and capecitabine drugs); Hiccup after chemotherapy	Drowsiness during menstruation
DIET PRACTISE	Regular	Vegetarian	Diet rich in vegetables	Diet rich in vegetables	Regular
PROBABLE TRIGGERING EVENT	Cortisone therapy for joint pains	Diet change and poor feeding (8 kg lost in a month) after dental surgery	Diet change: a meal of fish in a Chinese restaurant	Chemotherapy (Oxaliplatin, Capecitabine)	Infertility hormone therapy and ICSI-ET, but without an ongoing pregnancy
MISDIAGNOSIS AT ONSET	Depression; Unspecified hepatopathy	Infectious disease; Intestinal pseudo-obstruction; Portosystemic shunts	Poisoning; Infectious diseases; Drug abuse	Poisoning; Ischemia; Cancer; Hepatitis	Narcolepsy; Cancer
SIGN AND SYMTOMS OF ACUTE EPISODE					
Abdominal pain/Vomiting	No/Yes	Yes/Yes	Yes/Yes	No/No	No/No
Headache/Vertigo	Yes/Yes	No/Yes	No/No	No/Yes	No/No
Fever	No	Yes	No	No	Yes
Food refusal	Yes	Yes	No	No	No
Seizures	No	Yes	No	Yes	Yes
Hepatomegaly	No	No	No	Mild	No
Consciousness disturbances	Confusion; Drowsiness; Coma (2 d after onset)	Irritability; Confusion; Coma lasting 24 hours (5 d after onset); Subsequent coma (20 d after)	Confusion; Drowsiness; Coma (3 d after onset)	Slurred speech; Confusion; Hallucinations; Drowsiness; Coma (3 d after onset)	Drowsiness; Coma (2 d after onset)

Abbreviations: M male, F female, y years, d days, ICSI-ET intra cytoplasmatic sperm injection - embryo transfer.

Table 2 Laboratory findings and therapy of adult OTCD patients with fatal encephalopathy

	Pt 1 (M)	Pt 2 (M)	Pt 3 (M)	Pt 4 (M)	Pt 5 (F)
LABORATORY DATA					
Total bilirubin (mg/dl, n.v. <1.2)	1.4	5.4	7.9	Normal	2.8
ALT; AST (U/l, n.v. < 40)	62; 55	467; 226	128; 84	127; 97	81; 95
Ammonia (first measurement - maximum value, μmol/l, n.v. 50–80)	153-411	369-845	156-377	251-1145	362-901
Respiratory alkalosis (n.v.: blood pH 7.35-7.45, pCO ₂ 35-45 mmHg, pO ₂ 75-100 mmHg)	blood pH 7.47, –, –	blood pH 7.54, pCO ₂ 30, pO ₂ 142	blood pH 7.45, pCO ₂ 32, pO ₂ 202	blood pH 7.51, pCO ₂ 27, pO ₂ 223	blood pH 7.51, pCO ₂ 26, pO ₂ 274
^P Glutamine (μmol/l, n.v. 399–823)	2006	4580	Normal	1680	1060
^P Citrulline (μmol/l, n.v. 17–53)	Normal	Normal	14	3	10
^P Lysine; ^P Proline (μmol/l, n.v. 105–236; 117–332)	702; Normal	900; 667	-	-	462; Normal
^U Orotic acid excretion (mmol/mol creatinine, n.v. 0.2-1.1)	378	34	Normal	234	136
Neuroimaging	Normal at onset (CT); Cerebral edema (CT, 2 d later)	Normal at onset (CT); Cerebral edema (CT, 3rd d of the second coma)	Normal at onset (CT); Cerebral edema (CT, 3 d later)	Normal at onset (CT and MRI)	Normal at onset (CT); Cerebral edema (MRI, 2 d later)
THERAPY					
	PHN; Antibiotics, BCAA infusion and lactulose	PHN; BCAA infusion (first coma); Mannitol; Propofol and thiopental; UCD therapy: stop protein intake, high caloric intake, L-Arg and CVHDF	PHN, BCAA infusion; Mannitol; Lactulose; Antibiotics; UCD therapy: SB, SPB and L-Arg	PHN; Phenytoin, thiopental and curare; UCD therapy: SB, SPB, L-Arg and CVHDF	PHN; Midazolam, metamizole and hypothermia; BCAA infusion; UCD therapy: stop protein intake, high caloric intake, SPB, L-Arg and HD
Date of starting UCD therapy (days from onset)	None	2nd d from second coma	3rd d	3rd d	7th d
Ammonia after UCD therapy	None	Never normalized	Normal	Normal	Normal
Time for normalisation of ammonia under UCD therapy	None	None	4 d	1 d and a half	4 d

Abbreviations: ALT alanine aminotransferase, AST aspartate aminotransferase, – not available, ^Pplasma, ^Uurine, CT computed tomography, d days, MRI magnetic resonance imaging, PHN parenteral hydration and nutrition, BCAA branched chain amino acids, UCD urea cycle disorder, L-Arg L-arginine, CVHDF continuous veno venous hemodiafiltration, SB sodium benzoate, SPB sodium phenylbutyrate, HD hemodialysis.

Table 3 OTC gene mutations identified in adult OTCD patients with fatal encephalopathy

Patient (sex; origin)	Mutation	Exon	Functional domain	Comment	Mutation reference	Genetic family testing
Pt 1 (M; Italy)	c.119G > T (p.Arg40Leu)	2	Polar/CP binding domain (S1)	CpG dinucleotide	This report	Three HT females: mother (76 y), two nieces (13 and 22 y); HM brother (50 y); WT sister
Pt 2 (M; Italy and Japan)	c.119G > A (p.Arg40His)	2	Polar/CP binding domain (S1)	CpG dinucleotide; protein degradation under certain conditions; reported OTC activity 6%	[17]	Not performed
Pt 3 (M; Italy)	c.314G > A (p.Gly105Glu)	4	Polar/CP binding domain (turn)	-	This report	HT mother (43 y); HM grandfather (80 y); WT brother
Pt 4 (M; Italy)	c.622G > A (p.Ala208Thr)	6	Equatorial/ORN binding domain (H6)	CpG dinucleotide; reported OTC activity 4%	[19]	HT daughter (36 y)
Pt 5 (F; Italy)	c.829C > T (p.Arg277Trp)	8	Equatorial/ORN binding domain (H9), flexible loop	CpG dinucleotide; increased k_m for ORN; reported OTC activity 5%	[20]	Three HT females: mother (72 y), sister (42 y) and niece (18 y); six WT females and two WT males

Abbreviations: M male, F female, CP carbamyl phosphate, ORN ornithine, S strand or β -sheet, H α -helix, HT heterozygous, HM hemizygous, WT wild type, y years of family members at the time of the proband's acute episode.


promptly treated. An observational study of non-classical UCD including OTCD adults has been recently reported [3]. However, no information is available indicating the number of asymptomatic adult probands, or their clinical course or the potential role of precipitant factors. Herein we report previously asymptomatic OTCD adults to provide clues that might help recognition of OTCD in adult age, and discuss the environmental factors triggering initial and fatal hyperammonemic episodes.

The patient's dietary preference for vegetables should be considered as an important clinical clue, since voluntary protein avoidance is a characteristic eating behavior that UCD patients adopt in order to avoid postprandial headache or drowsiness [22].

Special attention should be given to the biological specimen collection, since biochemical marker determination is essential for UCD diagnosis, especially during the acute episodes and also in patients with fatal

outcome. In patients with acute unexplained encephalopathy is mandatory to perform blood gas analysis and plasma ammonia measurement as part of the basic work-up, even in the absence of liver dysfunction. Detection of respiratory alkalosis and hyperammonemia must address further metabolic investigations on plasma and urine to confirm or exclude UCD, without delaying the specific hyperammonemia treatment, as clinical outcome strictly correlates with the duration and peak level of hyperammonemia [4]. Analysis of plasma amino acids and urine orotic acid should be urgently performed in a specialist centre at initial detection of hyperammonemia. Glutamine levels and increased urinary orotic acid are the main biochemical markers for acute-phase OTCD. Citrulline and arginine levels are often low in LO-OTCD but may be normal outside the acute phase [23,24].

In Pt 3 the normal values of both plasma glutamine and urinary orotic acid, detected at first measurement



when only mild symptoms were present, were at odds with the suspicion of OTCD, but a final OTCD diagnosis was reached through molecular analysis. In Pt 2 we found high plasma and urinary levels of lactate during his comatose state. This finding is in line with Snodgrass 2004 [25] who reported lactic acidosis only in advanced phase of OTCD.

It has been reported that during acute OTCD episodes coagulopathy may occasionally appear as a consequence of liver dysfunction [26]. More recently, it has been emphasised that coagulation abnormalities are previously unidentified complications of OTCD also in a remission state [27]. In light of these findings, a diagnosis of OTCD and other UCD should be actively sought in any child or adult presenting with coagulopathy and/or liver failure of undetermined etiologies [28]. In Pt 2 we detected prothrombin deficiency, but is unknown if it was an expression of chronic hepatitis, or of OTCD or of both. In this patient the diagnostic process was severely complicated and delayed by many misdiagnoses, such as portosystemic shunt, as frequently described by Japanese authors [29].

Hyperlysineemia and hyperprolinemia, which have been reported as negative prognostic factors for OTCD [30], have been detected in 3 patients in our series. However, hyperprolinemia in Pt 2 may be secondary to hyperlactacidemia, probably because proline oxidase is inhibited by lactic acid [31].

Molecular analysis and mutational correlations to LO-OTCD

Molecular analysis is the first choice method for confirming an OTCD diagnosis, thus it would be advantageous that the emergency department staff promptly consult a clinical biochemical geneticist or clinical geneticist, even at the initial presentation if possible (see links: <http://www.orpha.net/consor/cgi-bin/index.php>, <https://www.eimd-registry.org/> and <https://rarediseasesnetwork.epi.usf.edu/ucdc/index.htm>). However, most of the *OTC* mutations are private and variants whose pathogenicity is unknown and sometimes difficult to ascertain are frequently found. Thus, *in silico* analysis, by combining different tools, may be useful for predicting variant effects.

The novel p.Arg40Leu mutation leads to destabilization of the *OTC* enzyme by the loss of a salt bridge or of MoRF (Molecular Recognition Feature) binding. The MoRFs represent a class of disordered regions that provide molecular recognition and binding functions to other proteins and undergo disorder-to-order transitions upon specific bindings [32]. The *in silico* results for p.Arg40Leu are in line with the suggestion that mutations affecting codons on the convex face of the *OTC* trimer, such as Arg 40, may alter the conformation of the C-terminus and hence

interfere with its interaction with other proteins or the membrane [11].

The novel p.Gly105Glu mutation leads to a destabilization of local structures because of changes in solvent accessibility and in charge and steric hindrance, finally resulting in a perturbation of the trimer assembly. Therefore, p.Gly105Glu seems to lead to a partially functional enzyme.

The known p.Arg40His, p.Ala208Thr and p.Arg277Trp mutations are also responsible for partial *OTC* enzyme deficiency. Although the enzymatic assay was not performed for the novel p.Arg40Leu, *in silico* data indicating the biochemical similitude between the two mutations p.Arg40Leu and p.Arg40His and the comparable clinical presentation of patients carrying such mutations, suggest that p.Arg40Leu is also correlated with residual enzymatic activity and LO-OTCD.

Four out of five identified mutations affect CpG islands and three of them arise in arginine. Arginine has a high mutational score, likely because four of the six codons encoding it contain CpG dinucleotides, which represent mutational hot spots [2]. Since the novel p.Arg40Leu mutation affects the same CpG island as the known recurrent c.119G > A (p.Arg40His) mutation, it is probable that p.Arg40Leu might also occur in additional families.

Correlation of OTCD unmasking with environmental factors

The acute disease expression in the patients we reported results from a combination of genetic and environmental factors. Exposure to new environmental or stress factors may induce an unusual nitrogen load or a significant catabolic event, which can briskly affect the patients' homeostasis and interfere with residual *OTC* activity, making it no longer sufficient to remove the increased amount of waste nitrogen generated. Some medications may also cause hepatic toxicity and subsequent additional impairment of already overwhelmed *OTC* activity in the liver. The identification in the patients' families of several healthy adults of both genders harboring the same mutations as the patients, corroborates the hypothesis that these mutations cause their pathogenetic consequences only when particular environmental conditions arise.

Cortisone is a glucocorticoid hormone with many therapeutic uses. High circulating concentrations of glucocorticoids are known to have a general catabolic effect by primarily enhancing protein turnover [33]. There are at least four reports of OTCD adults who developed acute hyperammonemic coma following steroid administration [5,34-36].

Fasting and surgery are commonly considered dangerous conditions for OTCD patients since they cause metabolic stress and are often accompanied by reduced

energy production and increased turnover of endogenous proteins [5,37-39]. Moreover, a role of high protein diets (e.g. Atkins' diet) in unmasking adult-onset OTCD has been previously described [40].

Besides a high protein intake as an obvious triggering factor in Pt 3, the possible precipitating role of monosodium glutamate (MSG) consumption, which is especially used in Asian cuisine as a flavor enhancer, could also be considered. MSG has been reported to accelerate gastric emptying of a protein-rich meal in humans, stimulating secretions from the exocrine and endocrine systems and leading to increased plasma glutamine concentrations [41]. Therefore, MSG ingested by our patient could have contributed to a more rapid overload of nitrogen and glutamine.

Chemotherapies are among the medications causing hepatic toxicity and affecting protein catabolism. Their side effects on the oro-gastrointestinal tract are indeed responsible for impairing dietary protein absorption and consequently accelerating degradation of endogenous proteins. A postchemotherapy hyperammonemic encephalopathy emulating OTCD has been described as a distinct syndrome of hyperammonemia in two young women with hepatocellular carcinoma, who resulted mutation-negative to *OTC* [42,43]. Since insertion/deletions or deep intronic mutations were not excluded, OTCD unmasked by chemotherapy could still be possible in these patients.

The precipitating environmental factor for the female patient is not obvious, but a potential role of sex hormones or hormonal drugs seems to be very likely. Menses are considered precipitants for acute hyperammonemia in UCD [44] and a relationship between sex hormones and ureagenesis in a woman with UCD has been reported [45]. At least three hypotheses might explain the OTCD unmasking in our patient: a) the physiological changes of the endometrium during the menstrual cycle, which produce large amounts of waste nitrogen and which may explain the drowsiness occurring in conjunction with menses; b) the direct action of endogenous sex hormones and/or hormonal drugs on the urea cycle by modulation of enzymatic expression and function; c) the toxic effects of infertility medication resulting in worsening of hepatic function, since these drugs are primarily metabolized in the liver.

An additional precipitant for the metabolic decompensation in our patients might have been parenteral nutrition, which provides more proteins than the patient usually expends entirely [46].

Conclusions

The diagnosis of OTCD in adults may be difficult, as clinical manifestations are non-specific and often episodic and laboratory findings can be normal outside the acute phase. Since LO-OTCD can be hidden and suddenly become

symptomatic under specific environmental factors, early suspicion/diagnosis is crucial to providing effective treatment in probands and to helping prevent clinical outbursts in other family members. This report raises awareness of emergency department staff in considering OTCD in the differential diagnosis of sudden neurological and behavioural disorders associated with hyperammonemia at any age and in both genders. Molecular analysis is the method of choice for confirming an OTCD diagnosis, for uncovering the carrier status in at risk family members and for providing genetic counselling and prenatal diagnosis. Future efforts should be aimed at further widening the knowledge about combined effect of genetic factors (i.e. mutations in the *OTC* gene, variants in modifier genes or epigenetic features) and environmental conditions in determining the phenotypic expression of OTCD.

Availability of supporting data

The data sets supporting the results of this article are included within the article and its additional files.

Additional files

Additional file 1: Text S1. Case reports.

Additional file 2: Table S2. Bioinformatic results for the novel p.Arg40Leu and p.Gly105Glu mutations.

Abbreviations

OTCD: X-linked ornithine transcarbamylase deficiency; UCD: Urea cycle disorder; CP: Carbamyl phosphate; ORN: Ornithine; LO-OTCD: Late onset OTCD; LC-MS/MS: Liquid chromatography-tandem mass spectrometry; Pt: Patient; CPS1: Carbamoyl phosphate synthetase I; NAGS: N-acetylglutamate synthase; MoRF: Molecular recognition feature; MSG: Monosodium glutamate.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

CC participated in the conception and design of the study, performed the molecular genetic studies, contributed to the analysis and interpretation of data and drafted the manuscript. MAD participated in the conception and design of the study, contributed to the analysis and interpretation of clinical and biochemical data and revised the article critically for important intellectual content. RP, MR, MB, FO, NGS and AC performed the acquisition of clinical findings and contributed to the discussion of data. SF and GLM performed the biochemical assays. SC contributed to the analysis and interpretation of genetic data. EP contributed to the analysis and interpretation of clinical and biochemical data and revised the article critically for important intellectual content. SDM performed the *in silico* analysis of new mutations and contributed to the discussion of genetic findings. RG contributed to the discussion of clinical data and revised the article critically for important intellectual content. AM participated in the conception and design of the study, coordinated the study, contributed to the analysis and interpretation of data and revised it critically for important intellectual content. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank the AMMeC (Associazione Malattie Metaboliche Congenite, Italia) and the Fondazione Ospedale Pediatrico A. Meyer ONLUS, Florence, Italy for continuing support.

Author details

¹Molecular and Cell Biology Laboratory, Pediatric Neurology Unit and Laboratories, Neuroscience Department, A. Meyer Children's Hospital, Viale Pieraccini 24, 50139 Florence, Italy. ²Metabolic and Muscular Unit, A. Meyer Children's Hospital, Florence, Italy. ³Rare Metabolic Diseases Unit, Department of Pediatrics, Fondazione MBBM, San Gerardo Hospital, Monza, Italy. ⁴Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy. ⁵Intensive Care Unit, S. Maria della Misericordia Hospital, Perugia, Italy. ⁶Department of Emergency Medicine, School of Medicine, Catholic University of the Sacred Heart, Rome, Italy. ⁷Intensive Care Unit, ASL Salerno 2, Eboli Hospital, Eboli, Italy. ⁸Newborn Screening Biochemistry and Pharmacology Laboratory, Pediatric Neurology Unit and Laboratories, Neuroscience Department, A. Meyer Children's Hospital, Florence, Italy. ⁹Department of Neurosciences, Psychology, Pharmacology and Child Health, University of Florence, Florence, Italy. ¹⁰Buck Institute for Research on Aging, Novato, CA, USA. ¹¹Pediatric Neurology Unit and Laboratories, Neuroscience Department, A. Meyer Children's Hospital, Florence, Italy.

Received: 1 April 2014 Accepted: 27 June 2014

Published: 16 July 2014

References

1. Brusilow SWHA: **Urea Cycle Enzymes**. In *The Metabolic and Molecular Bases of Inherited Disease*. Edited by Scriver CR, Beaudet AL, Valle D, Sly WS. New York: McGraw-Hill; 2001:1909–1963.
2. Numata S, Koda Y, Ihara K, Sawada T, Okano Y, Matsuura T, Endo F, Yoo HW, Aranz JA, Rubio V, Wermuth B, Ah Mew N, Tuchman M, Pinner JR, Kirk EP, Yoshino M: **Mutant alleles associated with late-onset ornithine transcarbamylase deficiency in male patients have recurrently arisen and have been retained in some populations**. *J Hum Genet* 2010, **55**:18–22.
3. Ruegger CM, Lindner M, Ballhausen D, Baumgartner MR, Beblo S, Das A, Gautschi M, Glahn EM, Grunert SC, Hennermann J, Hochuli M, Huemer M, Karall D, Kölker S, Lachmann RH, Lotz-Havla A, Möslinger D, Nuoffer JM, Plecko B, Rutsch F, Santer R, Spiekeroetter U, Staufner C, Stricker T, Wijburg FA, Williams M, Burgard P, Häberle J: **Cross-sectional observational study of 208 patients with non-classical urea cycle disorders**. *J Inherit Metab Dis* 2014, **37**:21–30.
4. Häberle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, Huemer M, Karall D, Martinelli D, Crespo PS, Santer R, Servais A, Valayannopoulos V, Lindner M, Rubio V, Dionisi-Vici C: **Suggested guidelines for the diagnosis and management of urea cycle disorders**. *Orphanet J Rare Dis* 2012, **7**:32.
5. Summar ML, Barr F, Dawling S, Smith W, Lee B, Singh RH, Rhead WJ, Sniderman King L, Christman BW: **Unmasked adult-onset urea cycle disorders in the critical care setting**. *Crit Care Clin* 2005, **21**:S1–S8.
6. Lichter-Konecki U, Nadkarni V, Moudgil A, Cook N, Poeschl J, Meyer MT, Dimmock D, Baumgart S: **Feasibility of adjunct therapeutic hypothermia treatment for hyperammonemia and encephalopathy due to urea cycle disorders and organic acidemias**. *Mol Genet Metab* 2013, **109**:354–359.
7. La Marca G, Casetta B, Zammarchi E: **Rapid determination of orotic acid in urine by a fast liquid chromatography/tandem mass spectrometric method**. *Rapid Commun Mass Spectrom* 2003, **17**:788–793.
8. Bisanzi S, Morrone A, Donati MA, Pasquini E, Spada M, Strisciuglio P, Parenti G, Parini R, Papadia F, Zammarchi E: **Genetic analysis in nine unrelated Italian patients affected by OTC deficiency: detection of novel mutations in the OTC gene**. *Mol Genet Metab* 2002, **76**:137–144.
9. Frishman D, Argos P: **Knowledge-based protein secondary structure assignment**. *Proteins* 1995, **23**:566–579.
10. Capriotti E, Fariselli P, Casadio R: **I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure**. *Nucleic Acids Res* 2005, **33**:W306–W310.
11. Shi D, Morizono H, Ha Y, Aoyagi M, Tuchman M, Allewell NM: **1.85-Å resolution crystal structure of human ornithine transcarbamoylase complexed with N-phosphonacetyl-L-ornithine. Catalytic mechanism and correlation with inherited deficiency**. *J Biol Chem* 1998, **273**:34247–34254.
12. Shi D, Morizono H, Yu X, Tong L, Allewell NM, Tuchman M: **Human ornithine transcarbamylase: crystallographic insights into substrate recognition and conformational changes**. *Biochem J* 2001, **354**:501–509.
13. Sobolev V, Sorokina A, Prilusky J, Abola EE, Edelman M: **Automated analysis of interatomic contacts in proteins**. *Bioinformatics* 1999, **15**:327–332.
14. Katoh K, Kuma K, Toh H, Miyata T: **MAFFT version 5: improvement in accuracy of multiple sequence alignment**. *Nucleic Acids Res* 2005, **33**:511–518.
15. Ashkenazy H, Erez E, Martz E, Pupko T, Ben-Tal N: **ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids**. *Nucleic Acids Res* 2010, **38**:W529–W533.
16. Oppliger Leibundgut EO, Liechti-Gallati S, Colombo JP, Wermuth B: **Ornithine transcarbamylase deficiency: new sites with increased probability of mutation**. *Hum Genet* 1995, **95**:191–196.
17. Tuchman M, Plante RJ, McCann MT, Qureshi AA: **Seven new mutations in the human ornithine transcarbamylase gene**. *Hum Mutat* 1994, **4**:57–60.
18. Yamaguchi S, Brailey LL, Morizono H, Bale AE, Tuchman M: **Mutations and polymorphisms in the human ornithine transcarbamylase (OTC) gene**. *Hum Mutat* 2006, **27**:626–632.
19. Van Diggelen OP, Zaremba J, He W, Keulemans JL, Boer AM, Reuser AJ, Ausems MG, Smeitink JA, Kowalczyk J, Pronicka E, Rokicki D, Tarnowska-Dziduszko E, Kneppers AL, Bakker E: **Asymptomatic and late-onset ornithine transcarbamylase (OTC) deficiency in males of a five-generation family, caused by an A208T mutation**. *Clin Genet* 1996, **50**:310–316.
20. Finkelstein JE, Hauser ER, Leonard CO, Brusilow SW: **Late-onset ornithine transcarbamylase deficiency in male patients**. *J Pediatr* 1990, **117**:897–902.
21. Rimbaux S, Hommet C, Perrier D, Cottier JP, Legras A, Labarthe F, Lemarcis L, Autret A, Maillot F: **Adult onset ornithine transcarbamylase deficiency: an unusual cause of semantic disorders**. *J Neurol Neurosurg Psychiatry* 2004, **75**:1073–1075.
22. Rowe PC, Newman SL, Brusilow SW: **Natural history of symptomatic partial ornithine transcarbamylase deficiency**. *N Engl J Med* 1986, **314**:541–547.
23. Cavicchi C, Malvagìa S, La Marca G, Gasperini S, Donati MA, Zammarchi E, Guerrini R, Morrone A, Pasquini E: **Hypocitrullinemia in expanded newborn screening by LC-MS/MS is not a reliable marker for ornithine transcarbamylase deficiency**. *J Pharm Biomed Anal* 2009, **49**:1292–1295.
24. Tuchman M, Holzkecht RA: **Heterogeneity of patients with late onset ornithine transcarbamylase deficiency**. *Clin Invest Med* 1991, **14**:320–324.
25. Snodgrass PJ: *Ornithine Transcarbamylase: Basic Science and Clinical Considerations*. Boston: Kluwer Academic Publishers; 2004.
26. Thurlow VR, Asafu-Adjaye M, Agalou S, Rahman Y: **Fatal ammonia toxicity in an adult due to an undiagnosed urea cycle defect: under-recognition of ornithine transcarbamylase deficiency**. *Ann Clin Biochem* 2010, **47**:279–281.
27. Ihara K, Yoshino M, Hoshina T, Harada N, Kojima-Ishii K, Makimura M, Hasegawa Y, Watanabe Y, Yamaguchi S, Hara T: **Coagulopathy in patients with late-onset ornithine transcarbamylase deficiency in remission state: a previously unrecognized complication**. *Pediatrics* 2013, **131**:e327–e330.
28. Samuel N, Politansky AK, Hoffman R, Itzkovich S, Mandel H: **Coagulopathy unmasking hepatic failure in a child with ornithine transcarbamylase deficiency**. *Isr Med Assoc J* 2013, **15**:777–779.
29. Watanabe A: **Portal-systemic encephalopathy in non-cirrhotic patients: classification of clinical types, diagnosis and treatment**. *J Gastroenterol Hepatol* 2000, **15**:969–979.
30. Harada E, Nishiyori A, Tokunaga Y, Watanabe Y, Kuriya N, Kumashiro R, Kuno T, Kuromaru R, Hirose S, Ichikawa K, Yoshino M: **Late-onset ornithine transcarbamylase deficiency in male patients: prognostic factors and characteristics of plasma amino acid profile**. *Pediatr Int* 2006, **48**:105–111.
31. Saudubray JM, Van Den Berghe G, Walter JH: *Inborn Metabolic Diseases: Diagnosis and Treatment*. fifthth edition. Berlin-Heidelberg: Springer-Verlag GmbH; 2012.
32. Mohan A, Oldfield CJ, Radivojac P, Vacic V, Cortese MS, Dunker AK, Uversky VN: **Analysis of molecular recognition features (MorFs)**. *J Mol Biol* 2006, **362**:1043–1059.
33. Lofberg E, Gutierrez A, Wernerman J, Anderstam B, Mitch WE, Price SR, Bergstrom J, Alvestrand A: **Effects of high doses of glucocorticoids on free amino acids, ribosomes and protein turnover in human muscle**. *Eur J Clin Invest* 2002, **32**:345–353.
34. Atiq M, Holt AF, Safdar K, Weber F, Ravinuthala R, Jonas ME, Neff GW: **Adult onset urea cycle disorder in a patient with presumed hepatic encephalopathy**. *J Clin Gastroenterol* 2008, **42**:213–214.
35. Hawley RJ: **Hyperammonia possibly due to corticosteroids**. *Arch Neurol* 2000, **57**:1085–1086.
36. Lipskind S, Loanzon S, Simi E, Ouyang DW: **Hyperammonemic coma in an ornithine transcarbamylase mutation carrier following antepartum corticosteroids**. *J Perinatol* 2011, **31**:682–684.

37. Chiong MA, Bennetts BH, Strasser SI, Wilcken B: **Fatal late-onset ornithine transcarbamylase deficiency after coronary artery bypass surgery.** *Med J Aust* 2007, **186**:418–419.
38. Hu WT, Kantarci OH, Merritt JL 2nd, McGrann P, Dyck PJ, Lucchinetti CF, Tippmann-Peikert M: **Ornithine transcarbamylase deficiency presenting as encephalopathy during adulthood following bariatric surgery.** *Arch Neurol* 2007, **64**:126–128.
39. Marcus N, Scheuerman O, Hoffer V, Zilbershot-Fink E, Reiter J, Garty BZ: **Stupor in an adolescent following Yom Kippur fast, due to late-onset ornithine transcarbamylase deficiency.** *Isr Med Assoc J* 2008, **10**:395–396.
40. Ben-Ari Z, Dalal A, Morry A, Pitlik S, Zinger P, Cohen J, Fattal I, Galili-Mosberg R, Tessler D, Baruch RG, Nuoffer JM, Largiader CR, Mandel H: **Adult-onset ornithine transcarbamylase (OTC) deficiency unmasked by the Atkins' diet.** *J Hepatol* 2010, **52**:292–295.
41. Zai H, Kusano M, Hosaka H, Shimoyama Y, Nagoshi A, Maeda M, Kawamura O, Mori M: **Monosodium L-glutamate added to a high-energy, high-protein liquid diet promotes gastric emptying.** *Am J Clin Nutr* 2009, **89**:431–435.
42. Chan JS, Harding CO, Blanke CD: **Postchemotherapy hyperammonemic encephalopathy emulating ornithine transcarbamoylase (OTC) deficiency.** *South Med J* 2008, **101**:543–545.
43. Winter SS, Rose E, Katz R: **Hyperammonemia after chemotherapy in an adolescent with hepatocellular carcinoma.** *J Pediatr Gastroenterol Nutr* 1997, **25**:537–540.
44. McGuire PJ, Lee HS, Summar ML: **Infectious precipitants of acute hyperammonemia are associated with indicators of increased morbidity in patients with urea cycle disorders.** *J Pediatr* 2013, **163**:1705–1710. e1701.
45. Grody WW, Chang RJ, Panagiotis NM, Matz D, Cederbaum SD: **Menstrual cycle and gonadal steroid effects on symptomatic hyperammonemia of urea-cycle-based and idiopathic aetiologies.** *J Inherit Metab Dis* 1994, **17**:566–574.
46. Felig DM, Brusilow SW, Boyer JL: **Hyperammonemic coma due to parenteral nutrition in a woman with heterozygous ornithine transcarbamylase deficiency.** *Gastroenterology* 1995, **109**:282–284.

doi:10.1186/s13023-014-0105-9

Cite this article as: Cavicchi et al.: Sudden unexpected fatal encephalopathy in adults with OTC gene mutations—Clues for early diagnosis and timely treatment. *Orphanet Journal of Rare Diseases* 2014 **9**:105.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

